424 results about "Lidocaine" patented technology

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

The present invention discloses a novel tape preparation containing lidocaine at a high concentration. A tape preparation containing lidocaine at a high content, which has a lidocaine content of 10 w / w % or more, can be produced by using a lactic acid salt of lidocaine, while preventing the precipitation of a crystal of lidocaine.

Methods and compositions are offered for reducing nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia), where intradermal delivery of lidocaine is maintained for a predetermined period of time. The lidocaine appears to specifically affect the damaged nerve fibers, while leaving the undamaged and normal nerve fibers with retention of response to other stimuli. Lidocaine formulations are provided which allow for the necessary dosage of the lidocaine in the dermis during the period of treatment. The formulation may be covered with an occlusive or non-occlusive dressing, which protects the lidocaine formulation from mechanical removal and enhances the transport of the lidocaine into the dermis. Long term relief is realized after maintenance of the administration of lidocaine has been terminated.

The invention discloses an LID-PEG-PLGA controlled-release nano microsphere and a preparation method thereof. The microsphere is the controlled-release microsphere which contains medicinal lidocaine and a degradable carrier. The degradable carrier contains polylactic-glycolic acid and PEG-2000. The mass percentage of the lidocaine in the controlled-release microsphere is 30 to 35 percent. The preparation method comprises the following steps of: preparing the carrier into matrix solution; dispersing the lidocaine into the matrix solution and preparing the lidocaine into an oil phase; mixing the oil phase and the aqueous solution of polyvinyl alcohol, and performing ultrasonic emulsification on the mixture under a water bath condition to obtain W / O-type protogala; mixing the W / O-type protogala and the aqueous solution of polyvinyl alcohol again, and further emulsifying the mixture into W / O / W-type complex emulsion; volatilizing the emulsion by reducing pressure at the normal temperature to obtain cured lidocaine-carried nano microsphere; and scattering, blending, packaging, freezing, sterilizing and the like. The medicament loading rate of the controlled-release nano microsphere can be up to 15 to 22 percent; the entrapment rate can be up to 68 to 78 percent; and the half-life period can be prolonged to 3 to 4 days. Therefore, the microsphere has relatively good effect of burst in the first day after the microsphere is taken and good effect of slow release in later days.

It is an object of the present invention to introduce carboxylic acid-functionalities suitable for coupling into the denatonium structure by means of simple synthesis, namely the synthesis of bitter principle derivatives based on the denatonium structure according to formula 1:For example, according to the invention, lidocaine derivatives may be reacted with carboxylated benzyl halogenides. The carboxylated denatonium derivatives of the present invention are especially applied in medicine, biology, medical engineering as well as cosmetics, the pharmaceutical, chemical, and foodstuff industry.

A method and pharmaceutical composition for treating the sexual dysfunction of premature ejaculation is disclosed. The pharmaceutical composition consists of a solution of one or more stimulants and a desensitizer. The stimulant is selected from the group comprising spearmint solution, peppermint solution, cool mint solution, pepper solution, alcohol, rubbing alcohol, ether, or any solution that will stimulate the penis to cause an erection. The desensitizer is selected from the group comprising benzocaine and lidocaine. The pharmaceutical composition is enclosed within a cotton swab applicator and is applied directly to the penis with the cotton swab applicator.

The invention relates to cream for dissolving wart, relieving neoplasm and detoxicating, which comprises the following components by weight portion: 0 to 3.0 portions of licorice, 0 to 3.0 portions of scutellaria, 0 to 3.0 portions of phellodendron amurense, 0 to 3.0 portions of rhubarb, 0 to 1.0 portion of menthol, 2 to 60 portions of sodium hydroxide (or potassium hydroxide), 0 to 10 portions of calcium hydroxide, and 0.75 to 1.0 portion of levobupivacaine hydrochloric acid (or toad venom, bupivacaine hydrochloric acid, lidocaine, dicaine or procaine or other local anesthetics). The sodium hydroxide (or the potassium hydroxide) and the calcium hydroxide of proper concentration can quickly dissolve protein, and melt the wart, the neoplasm and various inflammatory tissues in time from 1 minute to tens of minutes; the scutellaria, the phellodendron amurense and the rhubarb resist bacteria and virus; the licorice and the scutellaria adjust immune function, and inhibit adverse tissue reaction; the toad venom has anti-inflammatory, anti-cancer and local anesthetic functions; the menthol is fresh and cool, and can deodorize and stop pain; and the levobupivacaine hydrochloric acid or other local anesthetics has local anesthetic and paregoric functions.

A topical medicament for use in treating tissues comprising: an enhancer for facilitating non-invasive, transdermal delivery and / or enhancing metabolic effect of a therapeutic dosage of LEVULAN® KERASTICK™ (aminolevulinic acid HCl) into a tissue. The present invention provides a topical, transdermal medicament for use in treating tissues comprising an enhancer for facilitating non-invasive, transdermal delivery of a therapeutic dosage of comprising LEVULAN® KERASTICK™ (aminolevulinic acid HCl) into a tissue for example wherein the enhancing agent is comprising L.M.X.4®The enhancer may be selected from the group consisting of lidocaine, benzyl alcohol, carbomer 940, cholesterol, hydrogenated lecithin, polysorbate 80, propylene glycol, trolamine, vitamin E acetate and water or combinations thereof. The present invention, also, provides a pharmaceutical composition useful for treating tissues in humans and animals which comprises a therapeutically effective amount of LEVULAN® KERASTICK™ (aminolevulinic acid HCl) or pharmaceutically acceptable salt thereof in combination with a synergistically effective amount of at least one enhancer or pharmaceutically acceptable carrier wherein said enhancer is selected from the group consisting of lidocaine, benzyl alcohol, carbomer 940, cholesterol, hydrogenated lecithin, polysorbate 80, propylene glycol, trolamine, vitamin E acetate and water. The invention, also, provides a method of treating or preventing a human or animal afflicted by a diseases comprising topically administering a pharmaceutical composition which comprises of a therapeutically effective amount of aminolevulinic acid HCl in combination with an enhancer and / or a pharmaceutically acceptable carrier. The invention, also, provides a method wherein the composition further comprises a synergistically effective amount of an enhancer and / or pharmaceutically acceptable salt thereof wherein said enhancer is selected from the group consisting of lidocaine, benzyl, carbomer 940, cholesterol, hydrogenated lecithin, polysorbate 80, propylene glycol, trolamine, vitamin E acetate, water and combinations thereof.

The invention relates to an injection for treating hemangioma, which is prepared from interferon, dexamethasone, adrenaline, lidocaine and water for injection. The preparation method comprises dissolving pingyangmycin (8 mg) into 2% lidocaine injection to reach volume of 3 ml; dissolving interferon (3,000,000 unit) into water for injection to reach volume of 3 ml; mixing diluted pingyangmycin (2 ml), diluted interferon (1 ml), dexamethasone (1 ml), adrenaline (0.5 ml), 2% lidocaine (2.5 ml) and water for injection (3 ml); and making into injection. The injection has good curative effect on hemangioma, convenient application, and no restriction to medical treatment condition.